Novartis’s Remibrutinib Succeeds In Pivotal CSU Trials With Promise Of Liver Safety

 
• By Ayisha Sharma

The major’s BTK inhibitor candidate, remibrutinib, met the primary and secondary endpoints of two Phase III trials in chronic spontaneous urticaria, with unproblematic liver function results so far, suggesting it may avoid pitfalls faced by rivals.  

drawn outline of a liver on a blue background, post it with smiley face
Liver Toxicities Have Plagued Other BTK Inhibitors For Multiple Sclerosis • Source: Shutterstock

More from Clinical Trials

More from R&D